Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JCXH-221 by Immorna Hangzhou Biotechnology for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
JCXH-221 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According...